Discovering an effective new treatment for a rare type of leukemia

A recent scientific study showed effective results for a new treatment for a rare type of leukemia by up to 74%, as the new treatment works to genetically change the body’s immune cells.

“Ciltacaptagin Autolusil”, known by its trade name “Carfecti”, was subjected to testing in a clinical trial that included 419 patients with multiple myeloma, said oncologist Orev Odegade during the annual conference of cancer specialists hosted by the American Society of Clinical Oncology in Chicago, during which the results of the trials were presented. Carfecti has been shown to be significantly more effective than current patient options, and can be used safely at an early stage of treatment.

The study showed that in the clinical trial, half of the patients received “Carvikti”, while the second half were given a combination of currently commonly prescribed drugs, including chemotherapy and steroids, and concluded that after following the patients over a period of 16 months, it was found that “Ciltacaptagon Otolucel” reduces the risk of The disease progressed by 74%, compared to standard treatments.

Multiple myeloma affects seven out of every hundred thousand people annually, according to the Cleveland Clinic, and it is a type of leukemia that affects white blood cells called plasma cells, and may cause damage to bones, kidneys and the immune system.